Payment overview · 2025
General Payments
$52.54
3 reported records · 1 companies
Healthcare provider profile · identity verified
Bruce Daniel Willner, DO
Allopathic & Osteopathic Physicians|Family Medicine · YOUNGSTOWN, OH · NPI 1609853076
Verified facts
What the public records show
CMS Open Payments records show Bruce Daniel Willner, DO received $52.54 in general payments during 2025 across 3 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.54 | 100.0% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $52.54 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.54 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.54 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 679 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 628 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 444 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 313 | 70 |
| Eliquis | Apixaban | 294 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 254 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 51 |
| Potassium Chloride | Potassium Chloride | 194 | 37 |
| Furosemide | Furosemide | 188 | 53 |
| Mirtazapine | Mirtazapine | 183 | 39 |
| Losartan Potassium | Losartan Potassium | 177 | 49 |
| Metformin Hcl | Metformin Hcl | 177 | 40 |
| Carvedilol | Carvedilol | 170 | 35 |
| Montelukast Sodium | Montelukast Sodium | 168 | 38 |
| Metformin Hcl Er | Metformin Hcl | 167 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 61 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 163 | 44 |
| Bumetanide | Bumetanide | 148 | 23 |
| Farxiga | Dapagliflozin Propanediol | 144 | 20 |
| Famotidine | Famotidine | 142 | 28 |
| Simvastatin | Simvastatin | 138 | 31 |
| Gabapentin | Gabapentin | 135 | 36 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 135 | 39 |
| Omeprazole | Omeprazole | 135 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 27 |
| Allopurinol | Allopurinol | 127 | 29 |
| Prednisone | Prednisone | 122 | 84 |
| Tramadol Hcl | Tramadol Hcl | 122 | 26 |
| Valsartan | Valsartan | 113 | 18 |
| Lisinopril | Lisinopril | 112 | 32 |
| Sertraline Hcl | Sertraline Hcl | 109 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 23 |
| Ramipril | Ramipril | 98 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 21 |
| Jardiance | Empagliflozin | 94 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 21 |
| Spironolactone | Spironolactone | 85 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 18 |
| Ozempic | Semaglutide | 80 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 32 |
| Irbesartan | Irbesartan | 79 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 17 |
| Glimepiride | Glimepiride | 73 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 23 |
| Trazodone Hcl | Trazodone Hcl | 72 | 30 |
| Ezetimibe | Ezetimibe | 66 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 15 |
| Donepezil Hcl | Donepezil Hcl | 64 | 17 |
| Xarelto | Rivaroxaban | 61 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 59 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 12 |
| Pregabalin | Pregabalin | 58 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 15 |
| Levetiracetam | Levetiracetam | 57 | suppressed |
| Azithromycin | Azithromycin | 55 | 42 |
| Memantine Hcl | Memantine Hcl | 55 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 53 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | suppressed |
| Loperamide | Loperamide Hcl | 46 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 22 |
| Celecoxib | Celecoxib | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 35 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | 21 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 35 | suppressed |
| Amoxicillin | Amoxicillin | 34 | 27 |
| Tolterodine Tartrate | Tolterodine Tartrate | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 33 | suppressed |
| Torsemide | Torsemide | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 31 | 12 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 14 |
| Olanzapine | Olanzapine | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Galantamine Er | Galantamine Hbr | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 23 |
| Tradjenta | Linagliptin | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Fluvastatin Sodium | Fluvastatin Sodium | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | 17 |
| Budesonide | Budesonide | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Trulicity | Dulaglutide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52.54 · 3 records | ABBVIE INC. | QULIPTA, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error